Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 29, 2008Diabetes Obesity and Metabolism

Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EFEleuterio FerranniniCzech Academy of Sciences, Institute of PhysiologyVFVivian FonsecaPreventive CardiologyBernard ZinmanBernard ZinmanUniversity of North Carolina at Chapel Hill

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ferrannini et al. (2008) studied this question.

synapsesocial.com/papers/6a7df6eea7c6153d1433a178https://doi.org/10.1111/j.1463-1326.2008.00994.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes2004 · 714 citations
  2. 2Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes2007 · 121 citations
  3. 3The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients2007 · 242 citations
  4. 4Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes2005 · 362 citations
  5. 5Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance2007 · 154 citations